SODIUM PHENYLBUTYRATE MARKET ANALYSIS

Sodium Phenylbutyrate Market, By Application (Pharmaceutical, Food & Beverages, Others), By Distribution Channel (Direct Sales, Distributor Sales, Online Retail), By End-User (Hospitals and Clinics, Research Institutes, Food & Beverage Industry, Cosmetics Industry, Other Industries), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

New product launches

In 2020, Hikma Pharmaceuticals is a British multinational pharmaceutical company launched a generic version of sodium phenylbutyrate tablets in the U.S. This generic version is available in 500 mg and 1000 mg strengths.
In 2021, Acella Pharmaceuticals launched a generic version of sodium phenylbutyrate powder for oral suspension in the U.S. This generic version is available in a 0.94 gram/gram strength.

Acquisition and partnerships

In 2021, Hikma Pharmaceuticals is a British multinational pharmaceutical company acquired the rights to market sodium phenylbutyrate in the U.S from Salix Pharmaceuticals.
In 2022, Alvogen acquired the rights to market sodium phenylbutyrate in Europe from Orphan Europe.
In 2022, CSL Behring entered into a partnership with Oryzon Genomics to develop and commercialize sodium phenylbutyrate for the treatment of urea cycle disorders.